Highlights Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 17/04/2026 BST			5-day change	1st Jan Change
1,804.00 ^DKK	+0.78%		+0.78%	-11.00%

04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
04-14	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI

Highlights

04-14	Genmab Posts Higher Darzalex Net Sales in Q1	MT
04-14	Genmab Q1 Darzalex net sales at $3,964 mln	RE
04-13	Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian Cancer	CI
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-16	Genmab Wraps Up Share Repurchase Program	MT
03-16	Genmab completed share buy-back program on March 13	RE
03-16	H Lundbeck A S Presents New Phase 1b Data for Lu Af28996 and Advances Pipeline in Movement Disorders	CI
03-09	H. Lundbeck A/S Announces Last Patient Randomized in Phase 3 Mascot Trial	CI
02-19	BofA Bullish on Genmab's FY26 Catalyst Path; Buy Rating Maintained	MT
02-18	Genmab: 2025 miss and cautious 2026 targets erode investor confidence
02-18	Genmab FY oper profit up at $1,065 mln	RE
02-17	Genmab announces initiation of share buy-back program	RE
02-17	Genmab 2025 Net Profit Falls, Revenue Increases; 2026 Revenue Outlook Issued	MT
02-17	(GMAB) Genmab Expects 2026 Revenue Range $4.07B - $4.40B, vs. FactSet Est of $4.32B	MT
02-17	Genmab A/S Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-17	Genmab Provides Earnings Guidance for the Full Year 2026	CI
02-04	Fitch Highlights Genmab's Antibody Oncology Leadership in Final Rating	MT
01-21	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
01-20	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
01-16	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
01-16	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
01-07	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
01-07	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
12-29	Genmab Discontinues Development of Tumor Treatment Acasunlimab	MT
12-29	Genmab A/S Reaffirms Earnings Guidance for the Year 2025	CI